Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
September 09 2024 - 7:00AM
Business Wire
Novocure (NASDAQ: NVCR) announced today it will present a
real-world analysis of usage of its Tumor Treating Fields
(TTFields) therapy and survival outcomes in newly diagnosed
glioblastoma (ndGBM) patients at the European Society for Medical
Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona,
Spain.
The results of the real-world analysis suggest higher TTFields
therapy device usage is significantly associated with improved
survival outcomes in a broad population of ndGBM patients.
Novocure’s ESMO 2024 Data Presentation Details:
Poster #459: Association of Tumor Treating Fields Device
Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis
of Patients in the US Authors: Jennifer M. Connelly, Department
of Neurology, Medical College of Wisconsin, Milwaukee, WI, United
States; Santiago Cabezas-Camarero, Department of Medical Oncology,
Hospital Universitario Clínico San Carlos (IdISSC), Madrid, Spain;
Nick Avgeropoulos, Novocure, Inc., Portsmouth, NH, United States;
Patrick Conlon, Novocure, Inc., Portsmouth, NH, United States;
Gordon Chavez, Novocure, Inc., Portsmouth, NH, United States; Ori
Farber, Novocure, Ltd., Haifa, Israel Date: Monday,
September 16
Abstracts are available on the ESMO website,
esmo.org/meeting-calendar/esmo-congress-2024/programme.
Novocure has also sponsored an ESMO Colloquium, The Role of
Alternating Electric Fields in the Therapeutic Management of
Patients with Advanced Non-Small Cell Lung Cancer, which will be
held Monday, September 16, 13:00 - 14:30 CEST, in the Oviedo
Auditorium, Hall 3.
About Tumor Treating Fields
Tumor Treating Fields (TTFields) are electric fields that exert
physical forces to kill cancer cells via a variety of mechanisms.
TTFields do not significantly affect healthy cells because they
have different properties (including division rate, morphology, and
electrical properties) than cancer cells. These multiple, distinct
mechanisms work together to target and kill cancer cells. Due to
these multimechanistic actions, TTFields therapy can be added to
cancer treatment modalities in approved indications and
demonstrates enhanced effects across solid tumor types when used
with chemotherapy, radiotherapy, immune checkpoint inhibition, or
targeted therapies in preclinical models. TTFields therapy provides
clinical versatility that has the potential to help address
treatment challenges across a range of solid tumors. To learn more
about TTFields therapy and its multifaceted effect on cancer cells,
visit tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and X (Twitter).
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions and other more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2024, and subsequent
filings with the U.S. Securities and Exchange Commission. Given
these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not
rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof.
The Private Securities Litigation Reform Act of 1995 permits this
discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240909217183/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
Media: Catherine Falcetti media@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Oct 2024 to Oct 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Oct 2023 to Oct 2024